Toblli Jorge Eduardo, Cao Gabriel, Casas Gabriel, Mazza Osvaldo Néstor
Laboratory of Experimental Medicine, Hospital Alemán, Buenos Aires, Argentina.
Am J Hypertens. 2006 Dec;19(12):1226-32. doi: 10.1016/j.amjhyper.2006.05.016.
Erectile dysfunction is associated with high blood pressure and antihypertensive treatment, especially diuretics and traditional beta-blockers. Nevertheless, new beta-blockers such as nebivolol present some differences with respect to the classic beta-blockers. The aim of this study was to determine the functional and morphologic effects of nebivolol on penile structures in hypertensive rats.
During a 6-month period, male spontaneously hypertensive rat (SHR) and Wistar-Kyoto (WKY) rats were studied. The groups were as follows: 1) untreated SHR (Untreated-SHR); 2) SHR given nebivolol 10 mg/kg/day (SHR+N); 3) SHR given amlodipine 3 mg/kg/day (SHR+AML); and 4) untreated WKY (untreated-WKY). Cavernous smooth muscle (CSM) and vascular smooth muscle (VSM) from cavernous arteries, as well as collagen type III (COL III) in cavernous tissue, were evaluated.
After 6 months, SHR groups given nebivolol and amlodipine showed similar reductions in blood pressure compared with untreated SHR. However, only SHR+N and control WKY showed significantly lower values of CSM (P < 01), VSM (P < 01), and COL III (P < 01) when compared with untreated SHR and SHR+AML. In addition SHR+N showed a higher endothelial nitric oxide synthase expression in sinusoidal endothelium compared with SHR, and SHR+AML (P < 01). In vitro studies revealed that SHR+N displayed a better relaxation response to acetylcholine than untreated-SHR and SHR+AML (P < 01).
Nebivolol presented equivalent BP control compared with amlodipine. However, only nebivolol showed a significant better functional outcome with a protective role against structural changes in erectile tissue that are caused by arterial hypertension.
勃起功能障碍与高血压及抗高血压治疗有关,尤其是利尿剂和传统β受体阻滞剂。然而,新型β受体阻滞剂如奈必洛尔与经典β受体阻滞剂存在一些差异。本研究的目的是确定奈必洛尔对高血压大鼠阴茎结构的功能和形态学影响。
在6个月的时间里,对雄性自发性高血压大鼠(SHR)和Wistar-Kyoto(WKY)大鼠进行了研究。分组如下:1)未治疗的SHR(未治疗-SHR);2)给予奈必洛尔10mg/kg/天的SHR(SHR+N);3)给予氨氯地平3mg/kg/天的SHR(SHR+AML);4)未治疗的WKY(未治疗-WKY)。评估了海绵体平滑肌(CSM)、海绵体动脉的血管平滑肌(VSM)以及海绵体组织中的III型胶原(COL III)。
6个月后,给予奈必洛尔和氨氯地平的SHR组与未治疗的SHR相比,血压有相似程度的降低。然而,与未治疗的SHR和SHR+AML相比,只有SHR+N和对照WKY的CSM(P<0.01)、VSM(P<0.01)和COL III(P<0.01)值显著更低。此外,与SHR和SHR+AML相比,SHR+N的窦状内皮中内皮型一氧化氮合酶表达更高(P<0.01)。体外研究表明与未治疗-SHR和SHR+AML相比,SHR+N对乙酰胆碱的舒张反应更好(P<0.01)。
与氨氯地平相比,奈必洛尔能有效控制血压。然而,只有奈必洛尔显示出显著更好的功能结果,对动脉高血压引起的勃起组织结构变化具有保护作用。